rprx: the income statement

MyFinsight

For the quarter ending 2025-09-30, RPRX made $609,291K in revenue. $288,217K in net income. Net profit margin of 47.30%.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Income Statement	2025-09-30	2025-06-30	2025-03-31	2024-09-30
Total income and other revenues	609,291	578,665	568,247	564,690
Provision for changes in expected cash flows from financial royalty assets	12,135	-203,938	-127,140	-227,604
Provision for credit losses on unfunded commitments	766	92,535	-	-
Research and development funding expense	50,500	300,500	50,500	500
General and administrative expenses	118,734	179,769	110,705	56,720
Total operating expense/(income), net	182,135	368,866	34,065	-170,384
Operating income	427,156	209,799	534,182	735,074
Equity in (earnings)/losses of equity method investees	15,948	2,693	6,443	10,407
Interest expense	79,564	68,668	65,261	66,506
Gains on derivative financial instruments	4,000	-2,000	-1,000	3,000
(gains)/losses on equity securities	18,863	-30,553	-45,878	50,849
Gains on available for sale debt securities	52,480	-27,420	-3,281	57,680
Interest income	6,903	8,327	11,290	17,508
Other non-operating expenses/(income), net	-1,575	-1,543	-3,062	-1,654
Total other (income)/expense, net	17,055	-119,164	-100,749	71,284
Consolidated net income before tax	444,211	90,635	433,433	806,358
Income tax expense	0	0	0	0
Consolidated net income	444,211	90,635	433,433	806,358
Net income attributable to non-controlling interests	155,994	60,459	195,084	262,371
Net income attributable to royalty pharma plc	288,217	30,176	238,349	543,987

Basic (in dollars per share)	0.67	0.07	0.55	1.22
Basic (in shares)	431,887,000	423,514,000	435,480,000	447,628,000
Diluted (in dollars per share)	0.67	0.07	0.55	1.21
Diluted (in shares)	559,611,000	562,298,000	578,102,000	592,726,000